BRAF mutant PD-L1 positive metastatic musculoskeletal lesions from primary lung adenocarcinoma treated with combination vemurafenib and pembrolizumab: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
BRAF mutant PD-L1 positive metastatic musculoskeletal lesions from primary lung adenocarcinoma treated with combination vemurafenib and pembrolizumab: a case report ; volume:18 ; number:1 ; day:28 ; month:9 ; year:2024 ; pages:1-9 ; date:12.2024
Journal of medical case reports ; 18, Heft 1 (28.9.2024), 1-9, 12.2024
- Creator
-
Ngelangel, Corazon A.
Sy, Florge Francis
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13256-024-04773-z
- URN
-
urn:nbn:de:101:1-2411292109458.873554858651
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ngelangel, Corazon A.
- Sy, Florge Francis
- SpringerLink (Online service)
Other Objects (12)
Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer
Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma
Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer
Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma
Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer
Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer